CORE B Core B, the Biostatistics and Research Informatics Core of the City of Hope Lymphoma SPORE, provides information management and statistical expertise across all SPORE research activities, including study design, safety monitoring, data collection, data quality assurance, data analysis, and multicenter study site coordination. Core B will ensure that the proposed research hypotheses will be addressed with appropriate measures, tests, and interpretation, whether the data arise from genomic studies, basic science, translational, immunologic studies, or clinical trials. The centralized, comprehensive, and integrated framework of Core B assures each SPORE investigator access to statistical and informatics experts who have appropriate experience, interests and time to engage in the collaborative development of study designs, analysis plans, data analysis, interpretation, reporting, and abstract/manuscript preparation. Core B will also provide infrastructure for the management and integration of both existing and newly collected data and specimens through consistent and compatible data handling. The Core plays an integral role in the scientific development, execution, and analysis of all projects in the SPORE. Core B investigators have extensive experience in quantitative methods for biomedical applications, including clinical, basic, and translational science studies, with particular expertise in hematologic malignancy research. Core B is committed to collaboration to help ensure the scientific integrity of the SPORE investigations, by participating in regular Project and Program meetings, and providing rigorous and innovative input on all statistical and information management matters arising within the projects.
The specific aims of Core B are as follows:
Specific Aim 1. To support high quality data management through state-of-the-art information technologies, ensuring standardization, quality assurance, security, training, monitoring, data integration, decision support, reporting and multicenter coordination.
Specific Aim 2. To provide biostatistical support to the Projects, Cores and Programs, by consulting on the design, data monitoring, analysis, statistical modeling, visualization, interpretation, reporting and publication of data generated by SPORE activities.

Public Health Relevance

As a critical shared resource of the Lymphoma SPORE, the purpose of the Biostatistics and Research Informatics Core (Core B) is to provide the essential information management, quality assurance, experimental design, and biostatistical resources required to conduct the ongoing and planned investigations of lymphoid malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA107399-11A1
Application #
9418460
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119
Mei, Matthew G; Cao, Thai M; Chen, Lu et al. (2017) Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant 23:1861-1869
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31

Showing the most recent 10 out of 97 publications